Last updated on September 2018

An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

Brief description of study

This is an open-label Phase 3 study with a 2-week, double-blind, placebo-controlled, randomized drug withdrawal period to evaluate the safety and efficacy of TEV-50717 tablets in patients who have previously completed participation in Study SD-809-C-17, Study TV50717-CNS-30046, or Study TV50717-CNS-30060.

Clinical Study Identifier: TX212262

Find a site near you

Start Over

University of South Florida-Morsani College of Medicine

880 6th St. South St. Petersburg, FL United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.